| NCT ID | NCT02903160 |
| Title | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) |
| Recruitment | Recruiting |
| Gender | male |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Icahn School of Medicine at Mount Sinai |
| Indications | |
| Therapies |
Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone |
| Age Groups: | adult senior |